Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Dian Diagnostics GroupLtd Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Dian Diagnostics GroupLtd şirketinin toplam hissedar öz sermayesi CN¥9.8B ve toplam borcu CN¥3.7B olup, bu da borç-öz sermaye oranını 38.1% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥17.5B ve CN¥7.7B dir. Dian Diagnostics GroupLtd 'in FAVÖK'ü CN¥584.0M faiz karşılama oranı 2 dur. Şirketin CN¥2.2B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

38.1%

Borç/özkaynak oranı

CN¥3.75b

Borç

Faiz karşılama oranı	2x
Nakit	CN¥2.18b
Eşitlik	CN¥9.83b
Toplam yükümlülükler	CN¥7.71b
Toplam varlıklar	CN¥17.55b

Son finansal sağlık güncellemeleri

Dian Diagnostics GroupLtd (SZSE:300244) Seems To Use Debt Quite Sensibly

May 24

Recent updates

Dian Diagnostics Group Co.,Ltd. (SZSE:300244) Looks Inexpensive But Perhaps Not Attractive Enough

Aug 20

Returns On Capital Signal Tricky Times Ahead For Dian Diagnostics GroupLtd (SZSE:300244)

Jul 12

Dian Diagnostics GroupLtd (SZSE:300244) Will Pay A Smaller Dividend Than Last Year

Jun 10

Dian Diagnostics GroupLtd (SZSE:300244) Seems To Use Debt Quite Sensibly

May 24

Dian Diagnostics Group Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Apr 30

Investors Holding Back On Dian Diagnostics Group Co.,Ltd. (SZSE:300244)

Apr 22

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 300244 'nin kısa vadeli varlıkları ( CN¥13.2B ) kısa vadeli yükümlülüklerini ( CN¥5.0B ) aşıyor.

Uzun Vadeli Yükümlülükler: 300244 şirketinin kısa vadeli varlıkları ( CN¥13.2B ) uzun vadeli yükümlülüklerini ( CN¥2.7B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 300244 'nin net borç/öz sermaye oranı ( 16% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: 300244 'nin borç/öz sermaye oranı son 5 yılda 75.7% seviyesinden 38.1% seviyesine düştü.

Borç Kapsamı: 300244 'nin borcu işletme nakit akışı ( 43.1% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 300244 'in borcuna ilişkin faiz ödemeleri EBIT ( 2 x kapsam) tarafından iyi karşılanmıyor.

Dian Diagnostics GroupLtd Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Dian Diagnostics GroupLtd (SZSE:300244) Seems To Use Debt Quite Sensibly

Recent updates

Dian Diagnostics Group Co.,Ltd. to Report Q3, 2024 Results on Oct 24, 2024

New minor risk - Share price stability

Dian Diagnostics Group Co.,Ltd. Approves Interim Cash Dividend for the Year 2024, Payable on September 20, 2024

Dian Diagnostics Group Co.,Ltd. Approves Interim Cash Dividend for the Year 2024

Price target decreased by 15% to CN¥13.76

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Dian Diagnostics Group Co.,Ltd. (SZSE:300244) Looks Inexpensive But Perhaps Not Attractive Enough

Returns On Capital Signal Tricky Times Ahead For Dian Diagnostics GroupLtd (SZSE:300244)

Dian Diagnostics Group Co.,Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Dian Diagnostics GroupLtd (SZSE:300244) Will Pay A Smaller Dividend Than Last Year

Dividend reduced to CN¥0.06

Dian Diagnostics Group Co.,Ltd. Announces Dividend on share A for the Year 2023, Payable on June 13, 2024

Dian Diagnostics GroupLtd (SZSE:300244) Seems To Use Debt Quite Sensibly

Price target decreased by 7.5% to CN¥25.72

Consensus EPS estimates fall by 43%

Dian Diagnostics Group Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Investors Holding Back On Dian Diagnostics Group Co.,Ltd. (SZSE:300244)

Dian Diagnostics Group Co.,Ltd., Annual General Meeting, May 20, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 8.3% to CN¥28.27

Dian Diagnostics Group Co.,Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Dian Diagnostics Group Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 20, 2024

Dian Diagnostics Group Co.,Ltd. Announces Executive Appointments

Price target decreased by 9.9% to CN¥31.56

Third quarter 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 20%

Price target decreased by 8.0% to CN¥37.35

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Now 20% undervalued after recent price drop

Dian Diagnostics Group Co.,Ltd. Announces Final Cash Dividend for A Shares, Payable on 31 May 2023

Dian Diagnostics Group Co.,Ltd. Approves Cash Dividend for 2022

Price target decreased by 10% to CN¥38.72

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 18%

Consensus EPS estimates fall by 10%, revenue upgraded

Consensus EPS estimates fall by 43%

Dian Diagnostics Group Co.,Ltd. (SZSE:300244) announces an Equity Buyback for CNY 50 million worth of its shares.

Less than half of directors are independent

Consensus revenue estimates increase by 14%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 14%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Dian Diagnostics Group Co.,Ltd. Announces Final Cash Dividend on A Shares for 2021, Payable on 08 June 2022

Less than half of directors are independent

Dian Diagnostics Group Co.,Ltd. Announces Dividend for 2021

Now 20% undervalued

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Dian Diagnostics Group Co.,Ltd. Proposes Final Cash Dividend for 2021

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 21% undervalued after recent price drop

Now 23% undervalued after recent price drop

Price target decreased to CN¥48.50

Third quarter 2021 earnings released: EPS CN¥0.81 (vs CN¥0.64 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.63 (vs CN¥0.80 in 2Q 2020)

Investor sentiment improved over the past week

Price target decreased to CN¥52.85

Dian Diagnostics Group Co.,Ltd. Approved Final Cash Dividend for 2020

First quarter 2021 earnings released: EPS CN¥0.55 (vs CN¥0.011 in 1Q 2020)

Consensus EPS estimates increase to CN¥1.82

Full year 2020 earnings released: EPS CN¥1.29 (vs CN¥0.56 in FY 2019)

New 90-day low: CN¥32.92

Dian Diagnostics Group Co.,Ltd. to Report Fiscal Year 2020 Results on Apr 10, 2021

Investor sentiment deteriorated over the past week

New 90-day high: CN¥43.96

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target raised to CN¥53.63

New 90-day low: CN¥36.20

Analysts update estimates

Third quarter earnings released

Dian Diagnostics Group Co.,Ltd. to Report Q3, 2020 Results on Oct 28, 2020

Dian Diagnostics Group Co.,Ltd. Announces Board Elations

Hu Yong and Xu Min completed the acquisition of 10% stake in Zhejiang Di’an Diagnostic Technology Co., Ltd. from Chen Haibin and Lai Cuiying.